The U.S. Food and Drug Administration (FDA) has approved a new medication called Jascayd (bexotegrast) for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). These are chronic, progressive lung diseases that cause scarring in the lungs, making it harder to breathe over time. Jascayd is a type of drug called a phosphodiesterase 4 (PDE4) inhibitor, which works differently from other available treatments. It is taken as a pill, 18 milligrams twice a day, with or without food. For people who have trouble swallowing, the tablets can be mixed with water.
The approval was based on a large study called FIBRONEER-IPF, which included over 1,100 patients with IPF. The study showed that people taking Jascayd had a slower decline in lung function, measured by a test called forced vital capacity (FVC), over 52 weeks compared to those taking a placebo. A smaller second study provided additional support. The most common side effects reported were nausea, diarrhea, and headache.
This new approval gives patients and doctors another treatment option, especially for those who cannot tolerate or do not respond well to existing antifibrotic therapies. However, Jascayd is not a cure. It is meant to help slow the progression of the disease.
If you or a loved one has IPF or PPF, talk to your doctor about whether Jascayd might be a suitable option. Your healthcare team can help you weigh the potential benefits and risks based on your individual health situation.
